Bivatuzumab
Product Specifications
UNSPSC Description
Bivatuzumab (Anti-CD44 Recombinant Antibody; BIWA 4) is a humanized monoclonal antibody directed against CD44v6. CD44v6 could acts as a sarcoma target for CAR-redirected CIK cells[1].
Target Antigen
Others
Type
Inhibitory Antibodies
Related Pathways
Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bivatuzumab.html
Purity
95.0
Solubility
10 mM in DMSO
Smiles
[Bivatuzumab]
References & Citations
[1]Leuci V,et al. CD44v6 as innovative sarcoma target for CAR-redirected CIK cells. Oncoimmunology. 2018 Feb 15;7(5):e1423167.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99281/Bivatuzumab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99281/Bivatuzumab-SDS-MedChemExpress.pdf
Clinical Information
Phase 1
CAS Number
214559-60-1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1487729-01 0.02 mg (E-Coli)
Recombinant Rhodospirillum rubrum Carboxylate-amine ligase Rru_A2462 (Rru_A2462)
Ask
View Details